Anti-tumor necrosis factor-alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis

Gillian Franklin; Joel Greenspan; Sheng Chen

Anti-tumor necrosis factor-alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis

Ann Clin Lab Sci. 2009 Spring;39(2):192-5.

Authors

Gillian Franklin¹, Joel Greenspan, Sheng Chen

Affiliation

¹ Department of Pathology, Long Island Jewish Medical Center, The Long Island Campus of Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA.

PMID: 19429808

Abstract

It has been reported that anti-tumor necrosis factor-alpha therapy increases the risk of opportunistic infections including rare case reports of leishmaniasis. Here we report a case of latent cutaneous leishmaniasis, which was provoked by anti-tumor necrosis factor-alpha therapy in a patient with rheumatoid arthritis.

Publication types

Case Reports

MeSH terms

Adult
Amphotericin B / therapeutic use*
Animals
Anti-Bacterial Agents / therapeutic use
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use*
Antiprotozoal Agents / therapeutic use
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / complications*
Arthritis, Rheumatoid / drug therapy*
Biopsy
Female
Humans
Leishmania / isolation & purification
Leishmaniasis, Cutaneous / diagnosis*
Leishmaniasis, Cutaneous / pathology
Nasal Mucosa / parasitology
Nasal Mucosa / pathology
Nose / pathology*
Treatment Outcome
Tumor Necrosis Factor-alpha / immunology*

Substances

Anti-Bacterial Agents
Antibodies, Monoclonal
Antiprotozoal Agents
Antirheumatic Agents
Tumor Necrosis Factor-alpha
Amphotericin B